OncoCyte Corp (NAS:OCX)
$ 3.29 -0.07 (-2.08%) Market Cap: 43.97 Mil Enterprise Value: 42.66 Mil PE Ratio: 0 PB Ratio: 2.35 GF Score: 34/100

OncoCyte Corp Key Opinion Leader Presentation Part 1: Transplant Rejection Testing Transcript

Sep 22, 2021 / 05:00PM GMT
Release Date Price: $79 (+2.07%)
Sara Riordan
OncoCyte Corporation - Director of Medical Education

Presentation Part 1: Transplant Rejection Testing
Sep 22, 2021 / 05:00PM GMT

=====================
Corporate Participants
=====================
* Ronald A. Andrews
OncoCyte Corporation - CEO, President & Director
* Sara Riordan
OncoCyte Corporation - Director of Medical Education

=====================
Conference Call Participants
=====================
* Bruce David Jackson
The Benchmark Company, LLC, Research Division - Senior Equity Analyst
* Mark Anthony Massaro
BTIG, LLC, Research Division - MD & Life Science & Diagnostic Tools Analyst
* Michael Stephen Matson
Needham & Company, LLC, Research Division - Senior Analyst
* Thomas Flaten
Lake Street Capital Markets, LLC, Research Division - Senior Research Analyst
* Ekkehard Schuetz
* Michael Oellerich

=====================
-

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot